ReviewDiabetologia2010
Genetic variants affecting incretin sensitivity and incretin secretion.
Review in Diabetologia, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 46 citations in OpenAlex.
- Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD.Diabetes care · 2018Trial
- β-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity.The Journal of clinical endocrinology and metabolism · 2015Trial
- The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway.Diabetes · 2013Trial
- Pharmacogenetics of new classes of antidiabetic drugs.Bosnian journal of basic medical sciences · 2021Review
- Relationship BetweenPharmacogenomics and personalized medicine · 2021Article
- Glucagon-like peptide 1 (GLP-1).Molecular metabolism · 2019 · on this mapReview
- The Continuing Evolution of Precision Health in Type 2 Diabetes: Achievements and Challenges.Current diabetes reports · 2019Review
- Differential methylation of the type 2 diabetes susceptibility locus KCNQ1 is associated with insulin sensitivity and is predicted by CpG site specific genetic variation.Diabetes research and clinical practice · 2019Article
- Gene x Gene Interactions Highlight the Role of Incretin Resistance for Insulin Secretion.Frontiers in endocrinology · 2019Article
- Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.Physiological reviews · 2017Review
- Investigation of gene-diet interactions in the incretin system and risk of type 2 diabetes: the EPIC-InterAct study.Diabetologia · 2016Article
- Genetic susceptibility to type 2 diabetes and obesity: from genome-wide association studies to rare variants and beyond.Diabetologia · 2014Review
- Untangling the interplay of genetic and metabolic influences on beta-cell function: Examples of potential therapeutic implications involving TCF7L2 and FFAR1.Molecular metabolism · 2014Review
- Hypoglycemia after gastric bypass: the dark side of GLP-1.Gastroenterology · 2014Article
- Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Molecular diagnosis & therapy · 2012Review
- Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications.The review of diabetic studies : RDS · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent genome-wide association studies identified several novel risk genes for type 2 diabetes. The majority of these type 2 diabetes risk variants confer impaired pancreatic beta cell function. Though the molecular mechanisms by which common genetic variation within these loci affects beta cell function are not completely understood, risk variants may alter glucose-stimulated insulin secretion, proinsulin conversion, and incretin signals. In humans, the incretin effect is mediated by the secretion and insulinotropic action of two peptide hormones, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. This review article aims to give an overview of the type 2 diabetes risk loci that were found to associate with incretin secretion or incretin action, paying special attention to the potential underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.